Molecular Biology Reports

, Volume 37, Issue 1, pp 325–332

Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients

  • Katarzyna Kiwerska
  • Małgorzata Rydzanicz
  • Andrzej Kram
  • Martyna Pastok
  • Agata Antkowiak
  • Wenancjusz Domagała
  • Krzysztof Szyfter


CDKN2A gene belongs to the genes involved in cell cycle regulation. When is absent or inactivated by mutation or promoter hypermethylation a cell may undertake an uncontrolled proliferation. Inactivation of CDKN2A gene is observed in many human malignancies, including larynx cancer. In this study we investigated mutations in exon 1 and exon 2 of CDKN2A gene in a large group of 390 laryngeal cancers. We found 40 different alterations (17%) and nearly half of them was not described previously. Out of these alterations two transversions in codon 108: c.322G>C (Asp108His) and c.322G>T (Asp108Tyr) as well as a G>A transition in codon 110 (Trp110X) were found more frequently (altogether: 7 cases in codon 108 and 10 cases in codon 110). This result, concerning the location of these codons in the ankyrin repeat structures, may suggest that these two codons may be critical hot-spots in larynx carcinogenesis.


CDKN2A gene mutations Larynx cancer Ankyrin repeats Cell cycle 


  1. 1.
    Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707CrossRefPubMedGoogle Scholar
  2. 2.
    Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS (1998) 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 20:113–118CrossRefPubMedGoogle Scholar
  3. 3.
    Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Weghorst CM, Lang JC (1999) p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 119:285–288CrossRefPubMedGoogle Scholar
  4. 4.
    Akanuma D, Uzawa N, Yoshida MA, Negishi A, Amagasa T, Ikeuchi T (1999) Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncol 35:476–483CrossRefPubMedGoogle Scholar
  5. 5.
    Giefing M, Martin-Subero JI, Kiwerska K, Jarmuz M, Grenman R, Siebert R, Szyfter K (2008) Characterization of homozygous deletions in laryngeal squamous cell carcinoma cell lines. Cancer Genet Cytogenet 184:38–43CrossRefPubMedGoogle Scholar
  6. 6.
    Rocco JW, Sidransky D (2001) p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264:42–55CrossRefPubMedGoogle Scholar
  7. 7.
    Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440CrossRefPubMedGoogle Scholar
  8. 8.
    Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415–417CrossRefPubMedGoogle Scholar
  9. 9.
    Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686–692CrossRefPubMedGoogle Scholar
  10. 10.
    Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525–4530PubMedGoogle Scholar
  11. 11.
    Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995) Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas—relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 72:393–398PubMedGoogle Scholar
  12. 12.
    Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, Hagiwara K, Hussain SP, Xiong Y, Demetrick DJ, Harris CC (1996) Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer 65:734–739CrossRefPubMedGoogle Scholar
  13. 13.
    Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630–3633PubMedGoogle Scholar
  14. 14.
    Jares P, Fernández PL, Nadal A, Cazorla M, Hernández L, Pinyol M, Hernández S, Traserra J, Cardesa A, Campo E (1997) p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene 15:1445–1453CrossRefPubMedGoogle Scholar
  15. 15.
    Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T (2001) Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 37:498–504CrossRefPubMedGoogle Scholar
  16. 16.
    Tripathi Bhar A, Banerjee S, Chunder N, Roy A, Sengupta A, Roy B, Roychowdhury S, Panda CK (2003) Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol 129:642–650CrossRefPubMedGoogle Scholar
  17. 17.
    Grafström E, Egyházi S, Ringborg U, Hansson J, Platz A (2005) Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res 11:2991–2997CrossRefPubMedGoogle Scholar
  18. 18.
    Guo XQ, Wang SJ, Zhang LW, Wang XL, Zhang JH, Guo W (2007) DNA methylation and loss of protein expression in esophageal squamous cell carcinogenesis of high-risk area. J Exp Clin Cancer Res 26:587–594PubMedGoogle Scholar
  19. 19.
    Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118–1128CrossRefPubMedGoogle Scholar
  20. 20.
    Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A’rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaili-Shandiz E, Dadkhah E (2008) p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol 14:2055–2060CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050–5053PubMedGoogle Scholar
  22. 22.
    Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210–212CrossRefPubMedGoogle Scholar
  23. 23.
    Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG (1997) Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 14:811–818CrossRefPubMedGoogle Scholar
  24. 24.
    Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, Beleites E, Claussen U, von Eggeling F (1999) Tumor suppressor gene p16 (CDKN2A) mutation status and promotor inactivation in head and neck cancer. Int J Mol Med 4:61–65PubMedGoogle Scholar
  25. 25.
    Miracca EC, Kowalski LP, Nagai MA (1999) High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 81:677–683CrossRefPubMedGoogle Scholar
  26. 26.
    Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60:892–895PubMedGoogle Scholar
  27. 27.
    Poi MJ, Yen T, Li J, Song H, Lang JC, Schuller DE, Pearl DK, Casto BC, Tsai MD, Weghorst CM (2001) Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck. Mol Carcinog 30:26–36CrossRefPubMedGoogle Scholar
  28. 28.
    Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61:939–942PubMedGoogle Scholar
  29. 29.
    Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21:4231–4236CrossRefPubMedGoogle Scholar
  30. 30.
    Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A (2002) INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch 441:133–142CrossRefPubMedGoogle Scholar
  31. 31.
    Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M, Shibata T (2006) Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132:735–743CrossRefPubMedGoogle Scholar
  32. 32.
    Koscielny S, Dahse R, Ernst G, von Eggeling F (2007) The prognostic relevance of p16 inactivation in head and neck cancer. ORL J Otorhinolaryngol Relat Spec 69:30–36PubMedGoogle Scholar
  33. 33.
    Szukała K, Sowińska A, Wierzbicka M, Biczysko W, Szyfter W, Szyfter K (2006) Does loss of heterozygosity in critical genome regions predict a local relapse in patients after laryngectomy? Mutat Res 600:67–76PubMedGoogle Scholar
  34. 34.
    van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D (1994) Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156–1158PubMedGoogle Scholar
  35. 35.
    González MV, Pello MF, López-Larrea C, Suárez C, Menéndez MJ, Coto E (1995) Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1:1043–1049PubMedGoogle Scholar
  36. 36.
    Waber P, Dlugosz S, Cheng QC, Truelson J, Nisen PD (1997) Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a. Oncogene 15:1699–1704CrossRefPubMedGoogle Scholar
  37. 37.
    Yarbrough WG, Buckmire RA, Bessho M, Liu ET (1999) Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. J Natl Cancer Inst 91:1569–1574CrossRefPubMedGoogle Scholar
  38. 38.
    Ruas M, Brookes S, McDonald NQ, Peters G (1999) Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene 18:5423–5434CrossRefPubMedGoogle Scholar
  39. 39.
    Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114–116CrossRefPubMedGoogle Scholar
  40. 40.
    Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27–37CrossRefPubMedGoogle Scholar
  41. 41.
    Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15–21CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang B, Peng Z (2000) A minimum folding unit in the ankyrin repeat protein p16(INK4). J Mol Biol 299:1121–1132CrossRefPubMedGoogle Scholar
  43. 43.
    Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN (1997) Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061–2067CrossRefPubMedGoogle Scholar
  44. 44.
    Karsai S, Abel U, Roesch-Ely M, Affolter A, Hofele C, Joos S, Plinkert PK, Bosch FX (2007) Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol 211:314–322CrossRefPubMedGoogle Scholar
  45. 45.
    Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27–32CrossRefPubMedGoogle Scholar
  46. 46.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150–153PubMedGoogle Scholar
  47. 47.
    Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK (1995) Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11:663–668PubMedGoogle Scholar
  48. 48.
    Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK (1997) CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57:4868–4875PubMedGoogle Scholar
  49. 49.
    Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R (2002) Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. Carcinogenesis 23:645–655CrossRefPubMedGoogle Scholar
  50. 50.
    Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C (1999) Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155:105–113PubMedGoogle Scholar
  51. 51.
    Ueki T, Hsing AW, Gao YT, Wang BS, Shen MC, Cheng J, Deng J, Fraumeni JF Jr, Rashid A (2004) Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 10:1717–1725CrossRefPubMedGoogle Scholar
  52. 52.
    Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O’Maille P, Tsai MD (1998) Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell 1:421–431CrossRefPubMedGoogle Scholar
  53. 53.
    Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Załuga E, Maleszka R, Kładny J, Górski B, Cybulski C, Gronwald J, Kurzawski G, Lubinski J (2005) CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 65:835–839PubMedGoogle Scholar
  54. 54.
    Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23–26CrossRefPubMedGoogle Scholar
  55. 55.
    Jin C, Jin Y, Wennerberg J, Akervall J, Dictor M, Mertens F (2002) Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet 132:85–96CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Katarzyna Kiwerska
    • 1
  • Małgorzata Rydzanicz
    • 1
  • Andrzej Kram
    • 2
  • Martyna Pastok
    • 1
  • Agata Antkowiak
    • 1
  • Wenancjusz Domagała
    • 2
  • Krzysztof Szyfter
    • 1
    • 3
  1. 1.Department of Environmental MutagenesisInstitute of Human Genetics, Polish Academy of SciencesPoznańPoland
  2. 2.Department of Pathology, Faculty of MedicinePomeranian Medical UniversitySzczecinPoland
  3. 3.Department of Otolaryngology and Oncological LaryngologyUniversity of Medical SciencesPoznańPoland

Personalised recommendations